Hemab Launches With ‘Pipeline In An Asset’ Approach To Rare Blood Disorders
Raises $55m In Series A
Emerging Company Profile: Backed by investors including Novo Holdings, HealthCap and RA Capital Management, Hemab Therapeutics is bringing together strong technology and deep expertise to ‘leapfrog’ treatment for several rare bleeding and thrombosis disorders into the 21st century.
You may also be interested in...
BioInnovation Institute chief business officer Bobby Soni shares how the life sciences incubator sources entrepreneurs and science globally, and the range of tools it provides to translate this into commercially viable companies.
Lithuania’s life sciences sector has harnessed the country’s talent, infrastructure and government support to realize a decade of unprecedented growth. With the industry now maturing, can the Baltic state overcome challenges to become a significant European player?
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.